CDKL5 is a protein kinase that plays a key role for neuronal functions as testified by the onset of complex neuronal dysfunctions in patients with genetic lesions in CDKL5. Here we identify a novel interactor of CDKL5, IQGAP1, a fundamental regulator of cell migration and polarity. In accordance with a functional role of this interaction, depletion of CDKL5 impairs cell migration and impedes the localization of IQGAP1 at the leading edge. Moreover, we demonstrate that CDKL5 is required for IQGAP1 to form a functional complex with its effectors, Rac1 and the microtubule plus end tracking protein CLIP170. These defects eventually impact on the microtubule association of CLIP170, thus deranging their dynamics. CLIP170 is a cellular target of the neurosteroid pregnenolone; by blocking CLIP170 in its active conformation, pregnenolone is capable of restoring the microtubule association of CLIP170 in CDKL5 deficient cells and rescuing morphological defects in neurons devoid of CDKL5. These findings provide novel insights into CDKL5 functions and pave the way for target-specific therapeutic strategies for individuals affected with CDKL5-disorder.
Introduction
CDKL5-disorder (OMIM #300672) is a neuropathological condition that is caused by alterations in the X-linked cyclindependent kinase-like 5 gene (CDKL5) (1) . Mutations in CDKL5 were initially associated with atypical Rett syndrome (RTT) but the onset of intractable epilepsy within the first three months after birth and the virtual absence of a period of normal development distinguish CDKL5 disorder from RTT (2) . Besides epilepsy, patients with genetic lesions in CDKL5 are characterized by severe intellectual disability, hypotonia, gross motor dysfunctions, and autistic traits; some RTT-like features such as hand stereotypies can often be observed.
CDKL5 is a serine/threonine kinase with an N-terminal catalytic domain and long C-terminus that acts as a regulator of the catalytic activity and serves as a protein interaction surface (3) . Alternative splicing, which influences mainly the C-terminal region, is known to generate several CDKL5 isoforms of which CDKL5_1 (previous CDKL5 107 ) is the most abundant one in both human and mouse (4) . Expression studies in rodents have shown that CDKL5 is ubiquitously expressed but with highest levels in brain where the expression peaks in the first post-natal weeks; the protein is present also during embryogenesis and remains expressed in adult stages (3) .
The cellular functions of CDKL5 are still not fully understood but the presence of the protein both in the nucleus and in the cytoplasm of expressing cells suggests that it may influence various cellular processes (3) . The nuclear partners of CDKL5 count the epigenetic factor MeCP2, DNA methyltransferase 1, the splicing factor SC35, and histone deacetylase 4 (HDAC4) altogether suggesting a functional link between CDKL5 and gene expression (5) (6) (7) (8) . In neurons, cytoplasmic CDKL5 is distributed both in the soma and in the neuronal periphery where its levels are tightly regulated in an activity-dependent manner (9, 10) . In the cytoplasm CDKL5 is known to regulate several aspects of neuronal morphology such as axon formation and outgrowth at least in part through shootin1 (11) . Moreover, defects in dendritic arborization and neuronal migration were linked to impaired activation of Rac1, an interactor of CDKL5 (12) . Finally, in spines CDKL5 forms a complex with PSD-95 and NGL-1, regulating spine morphology and maintenance in vitro and in vivo (13, 14) .
At present, no cure exists for patients with CDKL5 disorder. However, pharmaceutical targeting of pathways belonging to GSK3b, Akt/mTOR, or HDAC4, which are deficient in mouse models of CDKL5 disorder, has already proven efficient in restoring some neuroanatomic and behavioral deficits in Cdkl5-null mice (8, 14, 15) . While these data raise hope that pharmaceutical intervention is possible for CDKL5 disorder, the field still needs to further disentangle the networks regulated by CDKL5 to provide the basis for the rationale design of therapeutic strategies.
The strong impact of CDKL5 on neuronal morphology suggests that the kinase may be involved in regulating cytoskeletal dynamics; however the molecular mechanisms linking CDKL5 to such processes are not known. In the current study, we describe a novel role of CDKL5 in controlling microtubule dynamics through IQ domain-containing GTPase-activating protein 1 (IQGAP1). IQGAP1 controls various cellular processes that depend on the reorganization of the cytoskeleton thanks to its capacity to interact both with actin and microtubule plus end tracking proteins (þTIP) (16) . We found that directional cell migration is impaired in the absence of CDKL5; moreover, downregulation of CDKL5 displaces IQGAP1 from the leading edge of the migrating cells and reduces its capacity to interact with Rac1 and the þTIP cytoplasmic linker protein 170 (CLIP170). Accordingly, loss of CDKL5 also reduces the capacity of CLIP170 to associate with and guide MTs within cells. CLIP170 has recently been identified as a cellular receptor of the neurosteroid pregnenolone (P5) that, through its binding to CLIP170, stabilizes the protein in its active conformation increasing its affinity for microtubules (17) . Intriguingly, we find that treatment with P5 enhances the association of CLIP170 with MTs and causes a robust rescue of morphological defects in CDKL5 deficient neurons. These findings provide novel insight into how CDKL5 dysfunctions contribute to the associated pathogenesis and pave the way for target-specific therapeutic strategies.
Results

IQGAP1 is a novel interactor of CDKL5
To understand the molecular network belonging to CDKL5, we searched for protein interactors through a yeast two-hybrid screening as already described (11) . Briefly, the C-terminus of hCDKL5 (amino acids 299-1030 of isoform CDKL5_5) (4) was used as bait to screen a human adult brain cDNA library. Among the 171 interacting clones, one corresponded to IQGAP1 (Fig. 1A) . IQGAP1 is the most studied of the three members of the IQGAP family proteins, which are evolutionarily conserved scaffold proteins involved in the regulation of diverse cellular processes such as cell migration, polarity, proliferation, cytoskeletal dynamics, vesicle transport and intracellular signaling through the interaction with numerous proteins (16) . Of relevance, one of the most well recognized roles of IQGAP1 is that of acting as a critical effector of Rac1 and Cdc42 in the regulation of cytoskeletal related events.
To gather evidence of a physical association between CDKL5 and IQGAP1 in vivo, lysates from P7 brains were used to immunoprecipitate IQGAP1; through the subsequent western blotting, we could detect CDKL5 in the immunoprecipitate (Fig. 1B) . The reciprocal experiment, in which IQGAP1 coprecipiated with immunopurified CDKL5, confirmed that the two proteins are capable of forming a cognate complex in vivo (Fig. 1C) . Further proof of the interaction was obtained coimmunoprecipitating overexpressed Myc-tagged CDKL5 and endogenous IQGAP1 from HeLa cells (Fig. 1D) . The identification of the physical association between IQGAP1 and CDKL5 prompted us to analyze whether the two proteins could possibly be detected in common subcellular regions. Both IQGAP1 and CDKL5 are known to accumulate at actin-rich sites under the cell membrane upon Rac1 activation (12, 18) . Exogenous expression of IQGAP1 in fibroblasts is known to induce the formation of an actin-rich leading edge depending on its own accumulation at this site. When we expressed GFP-IQGAP1 in COS-7 fibroblasts, we were able to detect, as expected, a strong signal corresponding to GFP-IQGAP1 at the leading edge of the overexpressing cells; interestingly, the signal corresponding to endogenous CDKL5 was superimposed to that of GFP-IQGAP1 (Fig. 1E) . Altogether, these data allow us to conclude that IQGAP1 is capable of forming a cognate complex with CDKL5 in the brain and cultured cells.
CDKL5 deficiency impairs cell migration and delocalizes IQGAP1 from the leading edge IQGAP1 exerts an important control of cell migration through the regulation of cytoskeletal structures and signaling pathways at the cell cortex (19) . To analyze whether CDKL5 might play a similar role in directional cell migration, we performed a wound-healing assay with HeLa cells silenced for CDKL5 (siCDKL5#1). In this assay, a linear scratch is introduced in a confluent monolayer of cells that start migrating towards the opposite site to close the wound. As shown in Figure 2A , the suppression of CDKL5 expression slowed down cell migration; indeed, after 24 h (t 24 ) the silenced cells had left a wound that appeared significantly wider than that of control cells. Our quantification illustrated that the relative wound width at 24 h was 38 66.8% for control cells and 67 610.2% for silenced cells (Fig. 2B) . Similar defects were observed in COS7 cells upon silencing with a second CDKL5 specific siRNA (Supplementary Material, Fig. S1 ). As IQGAP1, CDKL5 thus appears to be involved in cell migration.
During cell migration, IQGAP1 accumulates at the leading edge where it orchestrates the coupling of MTs with the actinenriched leading edges (19) . To analyze the involvement of CDKL5 in this accumulation, we first verified that silencing of CDKL5 does not influence IQGAP1 expression (Fig. 2C) and then compared the distribution of endogenous IQGAP1 at the leading edges of migrating control cells with those silenced for CDKL5 ( Fig. 2D and E) . As expected, a marked accumulation of IQGAP1 could be detected at the actin-enriched leading edge in control cells whereas there was a visible difference in cells suppressed for CDKL5. Our quantification of the fluorescence intensity of the IQGAP1 signal along a line crossing the leading edge revealed a peak in signal intensity in correspondence with the polarized cell membrane (indicated with an arrow; Fig. 2E ). Conversely, cells silenced for CDKL5 where not characterized by the specific accumulation of IQGAP1 at the leading edge. To exclude that the observed phenotypes were due to off-target effects, we performed rescue experiments in which CDKL5 was reintroduced into silenced cells together with GFP from a bicistronic cassette. Interestingly, we found that the localization of IQGAP1 at the leading edge could be restored through expression of wild-type CDKL5 but not a kinase-dead derivative (Fig.  2F ). Taken together, these results suggest that the loss of CDKL5 interferes with the enrichment of IQGAP1 at the cell cortex with repercussions on cytoskeletal dynamics and thus cell migration.
IQGAP1-Rac1-CLIP170 complex formation depends on CDKL5
At the molecular level, the connection of IQGAP1 with cell migration and polarity can be explained by its capacity to assemble a ternary complex containing also Rac1 and CLIP170 (18, 20) . In this complex, IQGAP1 is involved in stabilizing the actin meshwork at specific sites under the cell membrane by maintaining Rac1 in an activated state; on the other hand, the plus end tracking protein CLIP170 acts as an MT rescue factor facilitating MT growth (21) . Considering the above data linking CDKL5 to IQGAP1, we found it plausible that CDKL5 might be involved in regulating the formation of this ternary complex. To address this point, we silenced CDKL5 expression with two different CDKL5 specific siRNAs in COS7 cells, using as before a non-targeting siRNA as control, and immunoprecipitated IQGAP1 from the three cell lysates in order to analyze the amount of coprecipitating Rac1. By western blotting, we first evaluated the cell lysates used for the immunoprecipitation (IP) (Input): as illustrated in Figure 3A , we confirmed a noticeable silencing of CDKL5 expression that influenced neither IQGAP1 nor Rac1 levels. Moreover, western blotting of the immunocomplexes verified the efficient IP of IQGAP1 in both the control and siCDKL5 samples. Conversely, the amount of Rac1 that coprecipitated with IQGAP1 varied visibly; in fact, the percentage of Rac1 that could be detected in the pellets of the silenced samples was significantly reduced (means 6SEM: 62.3 612% and 33.36 64% for siCDKL5#1 and siCDKL5#2, respectively). In addition, we analyzed the capacity of IQGAP1 to interact with CLIP170 in the absence of CDKL5. In this case, we immunopurified CLIP170 from control and CDKL5 knock-down samples and quantified the amount of copurifying IQGAP1. As shown in Figure 3B , the CLIP170/IQGAP1 interaction was reduced to 49,96 619.0% and 49.18 619.0% when CDKL5 expression was suppressed with siCDKL5#1 and siCDKL5#2, respectively. Thus, we conclude that CDKL5 is required for IQGAP1 to associate efficiently with both Rac1 and CLIP170 suggesting that loss of the kinase influences the capacity of IQGAP1 to coordinate actin and MT networks.
CLIP170 dynamicity is altered in CDKL5 deficient cells
When the binding between endogenous CLIP170 and IQGAP1 is interrupted through expression of a dominant negative IQGAP1-derivative, CLIP170 is delocalized from the MT tips (18) . To further characterize the behavior of CLIP170 in the absence of CDKL5, we exploited GFP-tagged CLIP170, which accumulates at the plus end of growing MTs forming comet-like structures, and visualized its dynamic properties through time-lapse microscopy. Loss of fluorescence in the comet-like dashes is correlated with the dissociation of the þTIP from the MTs (22) . We thus expressed GFP-CLIP170 in COS7 cells 60 h after silencing of CDKL5 expression (siCDKL5#2). As expected, in control cells (siCtr) we observed the presence of filamentous GFP-positive comets that moved from the cell center towards the periphery as described by Perez et al. (23) . Conversely, in cells silenced for CDKL5 the comets appeared as dots and did not always move in a radial fashion ( Fig. 4A ; Supplementary Material, Movies S1 and S2). Moreover, we found that the length and duration of the GFP-CLIP170 decorated comets in a selected area close to the cell cortex, was significantly reduced in siCDKL5 cells with Pregnenolone enhances the binding of GFP-CLIP170 to microtubules in CDKL5-deficient cells CLIP170 activities are determined by the conformational change of the protein. When folded in a closed structure, CLIP170 has reduced affinity for its binding partners and MTs whereas an open extended conformation renders the protein active (24) . The above data showing reduced binding to IQGAP1 and MTs therefore indicate that CLIP170 is mainly in a closed inactive conformation in cells with reduced CDKL5 levels. CLIP170 has recently been identified as a cellular receptor for the neurosteroid pregnenolone (P5); by binding CLIP170, P5 stabilizes the extended conformation of the protein thus increasing its affinity for MTs and promoting MT polymerization (17) . We thus hypothesized that P5 might be capable of rescuing the cellular defects associated with CDKL5 through the stabilization of CLIP170.
To test this, we treated siCDKL5 COS7 cells (siCDKL5#2) expressing GFP-CLIP170 with P5 and analyzed as above the fluorescent comets. Intriguingly, we found that chronic treatment of siCDKL5 cells with P5 caused the GFP-CLIP170 signal to become more filamentous and the comets to move in a more radial manner without influencing CDKL5 expression ( Fig. 5A and B; Supplementary Material, Movies S3-S5). Moreover, the length and duration of the GFP-CLIP170 positive comets in P5-treated cells were significantly increased with respect to those of the control cells (Fig. 5C and D) .
P5 treatment normalizes axon length and polarization in CDKL5-deficient neurons
Encouraged by the positive effect of P5 on silenced COS7 cells, we found it interesting to analyze the capacity of the compound to restore neuronal defects linked to CDKL5. We recently published that primary hippocampal neurons silenced for CDKL5 are characterized by a defect in axon formation and outgrowth (11) . MTs play a crucial role in neuronal polarization by sustaining the transport of proteins and organelles for axon formation and the CLIPs are involved in stabilizing the MT network in the axonal growth cone (25) . In light of the above data, the aforementioned axonal defects in neurons devoid of CDKL5 might thus be linked to defects in MT dynamics. To test the effect of P5 we prepared primary hippocampal neurons from E18 mouse embryos and silenced CDKL5 expression at the day of plating through infection with lentiviral particles expressing GFP together with a shRNA against CDKL5 (shCDKL5) or, as control, against b-galactosidase (shLacZ). Neurons were treated for 72 h with P5 before fixation at 4 days in vitro (DIV) and immunostaining for GFP and the axonal marker Tau1. Parallel experiments were performed with the water-soluble P5-sulfate (P5-S), which like P5 promotes MT polymerization, or progesterone (P4), a metabolite of P5 devoid of any effect on CLIP170 (17) . Through western blot analysis, we confirmed the efficient silencing of CDKL5 in all shCDKL5 samples (Fig. 6A) . Correctly polarized neurons were recognized as those bearing a single axon with a strong distal staining for Tau1, whereas neurons with no axon or multiple axons were classified as non-polarized (Fig. 6B ). In line with our previous data, CDKL5 knock down interfered with neuronal polarization: a single axon could be identified in only 79.23 60.98% of shCDKL5 neurons as opposed to 91.62 60.42% of control neurons (Fig. 6C) . Moreover, also the mean axon length was reduced in CDKL5-depleted neurons with respect to the control ( Fig. 6D ; shLacZ 290.67 615.5 mm; shCDKL5 193.68 67.99 mm). Interestingly, the treatment with P5 or P5-S for three days was sufficient to completely correct axon specification; indeed, the number of polarized neurons was similar to that of nontreated control neurons. Conversely, P4 was incapable of restoring the defect linked to silencing of CDKL5. Similarly, both P5 and P5-S but not P4 were capable of normalizing axon length ( Fig. 6C-E) . Neither of the compounds affected polarization or axon length in shLacZ neurons (Table 1) . Altogether, P5 and P5-S are capable of rescuing neuronal defects linked to CDKL5 in young neurons.
Discussion
In the present study, we identified IQGAP1 as a novel interactor of CDKL5 and found that at least some IQGAP1 functions are impaired in the absence of CDKL5. IQGAP1 plays a major role in the regulation of cellular morphology, polarization and migration acting as a molecular scaffold that allows the concerted regulation of various cytoskeletal effector proteins (16) . During directional cell migration IQGAP1 accumulates at the leading edge of the migrating cells where it orchestrates the interaction between the microtubule and actin networks through the formation of a triple complex with activated Rac1 and CLIP170 (18) . We found that depletion of CDKL5 impedes the localization of IQGAP1 at the cell cortex and, consistent with data described in literature (12) , that the ablation of CDKL5 impairs cells migration. At the molecular level, we found that the capacity of IQGAP1 to interact with Rac1 and CLIP170 is weakened upon silencing of CDKL5. In such a scenario, we envisage that CDKL5 regulates cell migration, and possibly other cellular functions, through IQGAP1-dependent effects on the cytoskeleton.
CDKL5 has in the past been linked to the actin cytoskeleton (12); indeed, it was found to accumulate at actin rich cellular structures such as neuronal growth cones and membrane ruffles of growth factor stimulated fibroblasts where it colocalized with Rac1. Moreover, the role of CDKL5 in regulating neurite outgrowth was mediated by Rac1. We have noticed that actin bundles are less evident in cells silenced for CDKL5 (Fig. 2D) ; even if we have not analyzed the actin dynamics in more details in these studies, we speculate that the interaction of CDKL5 with IQGAP1 may provide an explanation for this observation and the published data. While we find the role of CDKL5 in regulating actin dynamics an interesting aspect for future studies, we found the yet uncovered link between CDKL5 and microtubule-related functions intriguing.
It is widely accepted that IQGAP1 functions are regulated by phosphorylation at specific residues. Indeed, in vitro studies have indicated that phosphorylation of IQGAP1 at Ser1441 and Ser1443 by PKC induces a conformational change releasing the protein from an autoinhibitory structure and facilitating its interaction with Cdc42 (26) . In line with this, a phospho-mimetic variant of IQGAP1 stimulates neurite outgrowth in N1E-115 cells (27) , indicating that phosphorylation influences the capacity of IQGAP1 to control cytoskeletal dynamics. Even if IQGAP1 phosphorylation by CDKL5 still needs to be determined, we showed that the effect of CDKL5 depletion on IQGAP1 localization could be restored by the re-expression of wild-type CDKL5 but not by a kinase dead derivative indicating that the catalytic activity of CDKL5 is required for IQGAP1 functions at the cellular cortex.
In particular, we imagine that CDKL5, by directly or indirectly phosphorylating IQGAP1, might induce a conformational change in the protein promoting its correct localization at the cellular cortex and facilitating its binding with Rac1 and CLIP170; future studies will address this issue. Disruption of the IQGAP1-CLIP170 interaction, either through silencing of IQGAP1 or through expression of a dominant negative IQGAP1 derivative, was reported to cause the displacement of CLIP170 from MTs and to generate a disorganized MT array (18, 19) . Consistently, through time-lapse imaging of CDKL5 deficient cells expressing EGFP-tagged CLIP170, we observed loss of fluorescent EGFP-CLIP170 comets and a less well-organized MT network. By binding the plus ends of MTs, þTIPs exert a major regulatory role on MT dynamics in part by increasing either the events of catastrophe or rescue (growth to shrinkage and shrinkage to growth, respectively). Moreover, the capture of MTs at the cell cortex is favored by the interaction of the þTIPs and specific factors localized under the plasma membrane (28) . CLIP170 in particular is known to act as a rescue factor that supports the growth and elongation of MTs towards the cell cortex where they are stabilized upon capture of IQGAP1. The dislodgment of IQGAP1 from the cell cortex and the reduced interaction between IQGAP1 and CLIP170 in the absence of CDKL5 are therefore likely to reduce the capture and stability of MTs at the cell cortex. As in Fukata et al. (18), we observed the displacement of EGFP-CLIP170 from MTs throughout the cytoplasm and not only at the cell cortex where the majority of IQGAP1 is normally localized. IQGAP1, which can be detected throughout the cytoplasm, is thus likely to influence CLIP170 functions not only at the cell cortex.
Because of its involvement in neurological disorders CDKL5 has mostly been studied for its neuronal functions and several reports have described the role of CDKL5 in regulating neuronal morphology. Interestingly, defective IQGAP1 and CLIP170 functions cause neuronal defects that largely overlap those described in neurons devoid of CDKL5. In fact, CLIP170 has been involved in axon formation through its capacity to stabilize MTs in the growth cone (25) and together with IQGAP1 it regulates dendritic arborization (20) . Finally, similar to Cdkl5-null mice, Iqgap1-knockouts are characterized by an increased number of filopodia-like spines and cognitive defects (29) and mutations in CLIP1 (CLIP170 ortholog) has been linked to intellectual disability in humans (30) . We thus speculate that the identification of IQGAP1 as a novel CDKL5 interactor may allow paving the way for a further understanding of the molecular mechanisms underlying the neuroanatomic and behavioral defects linked to CDKL5 dysfunctions.
As further support of the relevance of our findings for the role played by CDKL5 in neurons, we found that the neurosteroid pregnenolone or its sulphated derivative, P5-S, were capable of restoring neuronal polarization and axon outgrowth in neurons silenced for CDKL5.
P5 is derived from the precursor cholesterol in the brain as well as in non-neuronal tissues through the action of cytochrome P450cc (31) . The further metabolism of P5 leads to the synthesis of other neurosteroids that have diverse effects on brain functions. While some neurosteroids have genomic actions by activating gene expression, non-genomic actions depend on their interaction with membrane receptors or, as in the case of P5, with microtubule-associated proteins. Among the metabolites of P5, P5-S and allopregnanolone can target GABA A , NMDA, and Sigma1 receptors and thus modulate neurotransmission. Conversely, P5 has low affinity for such receptors and its mechanism of action has been reported to involve the above mentioned effect on microtubule dynamics through its direct binding to CLIP170 and MAP2, another microtubule binding protein (17, 32) . Moreover, P5 has lately caught interest by acting as an allosteric negative modulator of the type-1 cannabinoid (CB1) receptor, thus being capable of protecting the brain from cannabis intoxication (33) .
Even if further studies are needed to define in more details the molecular mechanism underlying the positive effect of P5 and P5-S on CDKL5-deficient neurons, we consider likely the involvement of CLIP170. Considering that P5 was capable of restoring the association of CLIP170 with MTs in proliferating CDKL5-deficient cells, we hypothesize that a similar mechanism may be involved also in silenced neurons. Indeed, both P5 and P5-S are capable of activating CLIP170 by directly binding the protein and inducing its open conformation, whereas P4, a metabolic P5 derivative that does not bind CLIP170 was incapable of restoring defective axon formation (17) .
Although further studies are needed to fully understand which of the various morphological and molecular CDKL5 associated defects that can possibly be restored by P5, our studies may have interesting implications for patients with mutations in CDKL5. In the brain, reduced levels of P5 have been associated with aging and neurodegenerative disorders (34) ; it will thus be interesting in the future to analyze whether the levels of P5 or its metabolites are reduced in patients with CDKL5 disorder. If this were the case, considering the neuroprotective potential of P5 (35), we can assume that the neuronal damage caused by the frequent seizures in these patients might not be sufficiently attenuated by the neurosteroid.
Moreover, administration of P5 was found to enhance memory and cognition in rodents (36) . In humans, clinical testing of pregnenolone proved its antidepressive and -psycotic effects and the drug was well tolerated with a positive safety profile (37, 38) . Therapeutic strategies, including drug-based therapies, are still missing for patients with CDKL5 disorder. Based on our results, we find it intriguing to speculate that P5 might represent an interesting candidate for this group of patients. However, when considering the clinical applications of P5, it is important to take into account the possible effects of its metabolites. The development of synthetic steroids maintaining the specific action of P5 may thus represent interesting therapeutic compounds for various neurological disorders, including CDKL5 disorder.
Materials and Methods
Ethical statement
Protocols and use of animals were approved by the Animal Ethics Committee of the University of Insubria and in accordance with the guidelines released by the Italian Ministry of Health. Adult mice were euthanized by cervical dislocation, while neonates were sacrificed by exposure to CO2 followed by decapitation.
Plasmids pEGFP-IQGAP1 (plasmid #30112; Addgene) (39) . mEmerald-CLIP170-N-18 (plasmid #54044; Addgene). pMyc-CDKL5 (RefSeq AY217744) (40) . pCAG-mCDKL5-ires-GFP, pCAG-mCDKL5-K42R-ires-GFP (RefSeq NP_001019795) (11).
Antibodies and reagents
The following antibodies (Abs) were used: anti-a-tubulin (Sigma-Aldrich, T6074), anti-CDKL5 (Sigma-Aldrich, HPA002847; Santa Cruz, sc-376314), anti-GFP (Roche, 1814460), anti-IQGAP1 (Santa Cruz, sc-10792), anti Rac1 (BD Transduction Laboratories, 610650), anti-CLIP170 (Genetex, GTX117504; Santa Cruz H-300, sc-25613), anti-Tau1 (Millipore, MAB3420), anti-Tuj1 (Covance, MMS-435P). Phalloidin-TRITC Conjugates (Sigma-Aldrich P1951). HRP-conjugated goat anti-mouse or anti-rabbit secondary Abs for immunoblotting, DAPI, and secondary Alexa Fluor antirabbit and anti-mouse Abs for immunofluorescence (IF) were purchased from Thermo Scientific. Pregnenolone (P5), pregnenolone sulfate (P5-S) and progesterone (P4) were from Sigma Aldrich.
Yeast two-hybrid screening
The yeast two-hybrid screening was performed as already descried by Hybrigenics Services, S.A.S, Paris, France (http://www. hybrigenics-services.com) (11) . The C-terminus of human CDKL5_5 (amino acids 299-1030; GenBank accession number gi: 83367068) was used as bait to screen a random-primed Human Adult Brain cDNA library.
Cell cultures, RNA interference (RNAi) and transfections
HeLa and COS7 cells were maintained in DMEM (Dulbecco's modified Eagle's medium; Sigma-Aldrich) supplemented with 10% FBS, L-glutamine, 100 units/ml penicillin, and 100 lg/ml streptomycin at 37 C with 5% CO2.
For siRNA transfection, cells were cultured in 6-or 12-well dishes and 20 nM siRNA oligonucleotides targeting CDKL5, or a control siRNA (siCdkl5#1 5'CTATGGAGTTGTACTTAAA3', siCdkl5# 2 5'GCAGAGTCGGCACAGCTAT3', siCtr. 5'CGUACGCGGAAUACU UCGATT3') were transfected using LipofectamineTM RNAiMAX (Life Technologies Incorporated). For plasmid transfection, LipofectamineTM 3000 (Life Technologies Incorporated) was used.
Primary hippocampal cultures were prepared from embryonic day 17 (E17) CD1 mouse embryos, considering the day of the vaginal plug as E0, as described previously (9) and plated on poly-L-lysine coated plates (densities: 3.75x10 3 /cm 2 ). Infection of hippocampal neurons was performed by adding lentiviral particles 5 h after plating. Silencing of CDKL5 expression was obtained with a shCDKL5 targeting the sequence GCAGAG TCGGCACAGCTAT (corresponding to siCDKL5#2); a shRNA against LacZ was used as control.
Western blotting and immunoprecipitation
Cells were lysed with lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, protease inhibitor cocktail (Sigma Aldrich) and PhosSTOP (Roche)). After 30 min on ice, the lysates were clarified by centrifugation and the supernatants collected. Samples were separated by either 10 or 8% SDS-PAGE, transferred to nitrocellulose membranes, and blocked in 5% non-fat milk in TBS (20 mM Tris-HCl, pH 7.5, 150 mM NaCl) with 0.2% Tween-20 (T-TBS 
Immunofluorescence
After fixation in 4% paraformaldehyde cells were blocked in PBS w 5% horse serum, 0.2% Triton X-100 before incubation with the appropriate primary Ab overnight at 4 C and subsequently with the secondary Ab for 1h at room temperature. DNA was stained with DAPI and slides were mounted with ProLong Gold antifade reagent (Life Technologies). The analysis was performed at a NikonEclipse Ni upright microscope.
Wound healing assay
Three days after siRNA transfection, confluent cells were scratched with a 200 ll tip and allowed to migrate for 24 h upon which they were fixed and stained with DAPI to visualize the nuclei. Images were taken with a X10 objective and the wound width analyzed at >10 positions along each wound in three independent experiments.
Analysis of IQGAP1 localization at the leading edge IQGAP1 fluorescence intensity was measured using ImageJ analysis software along a segment of 15 lm perpendicular to the leading edge that was subdivided in 3 lm long smaller segments (positioning the central one in correspondence to the cell membrane). The mean pixel intensity was calculated for each of the five sub-segments.
Measurement of comet length and lifetime
For time-lapse imaging COS7 cells were transfected with the indicated siRNAs and 60 h after with pGFP-CLIP170; microscopy analysis was performed after another 24 h. P5 treatment was performed incubating cells with P5 1 mM or with 0.032% EtOH (Sigma Aldrich) as vehicle control for three days (starting treatment 24 h after siRNA transfection). Fluorescence in the specimens was imaged every 3 s for 3 min with a confocal laser-scanning microscope (model TCS SP8; Leica) with a 63X NA 1.2 oil immersion objective (Leica). Comet length and life-time was analyzed using the tracking function of the MTrackJ plug-in of ImageJ software.
Analysis of neuronal polarization and axon length
Hippocampal neurons were silenced at DIV0 and treated at DIV1 with 20 lM P5-S, 1 lM P5 or 1 mM and 20 lM P4 or with vehicle (0.032% EtOH, Sigma Aldrich).
Neuronal polarization was analyzed at DIV4 by staining with the axonal marker Tau1. Neurites with a significant intensity of Tau-1 staining increasing along the proximal to distal axis were counted as axons. Neurons were classified as polarized (one axon) or unpolarized (either lacking an axon or with multiple axons). Axon length was analyzed with ImageJ using the NeuronJ plugin to compute the path from the beginning to the end of the axon.
Data analyses
Data quantification, including cell migration, comet length and lifetime, and protein interaction were analyzed with Prism software (GraphPad) and are shown as mean 6 SEM. Two-tailed Student's t-tests or Anova were used for statistical analyses. Probability values of P < 0.05 were considered as statistically significant.
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